Conclusion
XDR A. bumannii, XDR, XDR A. bumannii VAP
The use of inhaled tobramycin/fosfomycin in cases with XDR Studies on adjunctive inhaled antibiotics for the treatment of XDR A. bumannii VAP are limited. This open‐lable randomized controlled trial focused on the efficacy of inhaled colistin and inhaled fosfomycin/tobramycin for the treatment of VAP caused by XDR A. bumannii. The use of inhaled tobramycin/fosfomycin leads to increased recovery rate and reduced duration of treatment in patients with XDR A. bumannii VAP.


